The University of Kansas Cancer Center

https://www.kucancercenter.org/

 

KU ASCO 2019 Updates on Hepatobiliary Cancer: Pembrolizumab vs. Best Supportive Care, Nivolumab Alone vs. Combo, and Genetic Targets

422 views
August 21, 2019
Comments 0
Login to view comments. Click here to Login